Abido OY, Abotaleb MM, Yehia N, El-Deeb AH, Amer AM, El-Sanousi AA

Language: English
References: 20
Page: 143-150
PDF size: 534.27 Kb.

ABSTRACT

Rabbit hemorrhagic disease is a contagious viral disease of rabbits controlled by vaccination. The present study was aimed to diagnose rabbit hemorrhagic disease from 11 infected farms from Qalubia governorate during 2019 and to prepare homologous vaccine against rabbit hemorrhagic disease virus 2. For this purpose, 11 liver samples were collected from suspected cases and subjected to detection and identification of circulating rabbit hemorrhagic disease virus. Ten samples were confirmed to be rabbit hemorrhagic disease virus using hemagglutination test, animal inoculation and reverse transcriptase polymerase chain reaction. Sequencing and phylogenetic analysis of two isolates (R5&R6) revealed the presence of rabbit hemorrhagic disease virus 2 (A/Qalubia/2019 and B/Qalubia/2019) under accession number MT07629 and MT067630 respectively. The inactivated rabbit hemorrhagic disease virus vaccines were prepared using Montanide ISA 206 oil or aluminum hydroxide gel adjuvants. Prepared vaccines were inoculated subcutaneously in susceptible rabbits and submitted to sterility, safety and potency tests. Obtained results showed that mean hemagglutination inhibition titer for aluminum hydroxide gel vaccine was 6,7.7,8.9 and 9.1 log2 while, Montanide vaccine reached to 6.7,8.7,9.2 and 9.5 log2 at 1st, 2nd, 3rd, and 4th weeks post vaccination, respectively. Immunized rabbits with Montanide vaccine showed better protection reach to 70%, 90%, 100% and 100% when compared to aluminum hydroxide gel vaccine 60%, 70%, 90% and 90% at 1st, 2nd, 3rd and 4th weeks post vaccination respectively. It was concluded that newly emerged rabbit hemorrhagic disease virus 2 was isolated from suspected cases. The two prepared vaccines were sterile, safe and potent. The oily adjuvanted rabbit hemorrhagic disease virus 2 vaccine stimulated an earlier and higher humoral immune response than the aluminum hydroxide gel adjuvanted vaccine. This humoral immune response achieved significant level of protection.

REFERENCES

1. Dalton KP, Abrantes J, Lopes AM, Nicieza I, Álvarez AL, Esteves PJ, Parra F. Complete genome sequence of two rabbit hemorrhagic disease virus variant b isolates detected on the Iberian Peninsula. Arch Virol.2015;160(3):877– 81.

2. Bazid AH, AboElkhair MM, Abdel-Razik AG, Salim R, Sultan HA, Hussein HA. Molecular characterization of a hemagglutinating and non-hemagglutinating rabbit hemorrhagic disease virus from Egypt. Alex. J. Vet. Sci.2015;45(1):1-5.

3. Ismail MM, Mohamed MH, El-Sabagh IM, Al-Hammadi MA. Emergence of new virulent rabbit hemorrhagic disease virus strains in Saudi Arabia. Trop. Anim. Health Prod. 2017;49(2):295–301.

4. Wang X, Xu F, Liu J, Gao B, Liu Y, Zhai Y, et al. Atomic model of rabbit hemorrhagic disease virus by cryo-electron microscopy and crystallography. PLoS Pathog.2013;9(1):e1003132. d.o.i:10.1371/journal.ppat.1003132.

5. OIE. World Organization for Animal Health. Viral hemorrhagic disease of rabbits. En: Manual of diagnostic tests and vaccines for terrestrial animals (mammals, birds, bees). Paris: OIE;2018.p:1389-1406. Available from: https://www.oie.int/.

6. Ghanem IA, Ismail AN. Occurrence of rabbit hemorrhagic disease in Sharkia province. Zagazig Vet J.1992;20:491–502.

7. Salman, OG. Further studies on hemorrhagic viral disease in rabbits in Egypt. [Ph. D. Thesis]. Cairo: Cairo University;2007.

8. Hemida RE, Khaliel SA, Al-Ebshahy EM, Abotaleb MM. Comparative study between the isolated rabbit hemorrhagic septicemia virus and available vaccine strain. Inter. J. Vet. Sci.2020;9(2):189-95.

9. Le Gall-Recule G, Zwingelstein F, Boucher S, Le Normand B, Plassiart G, Portejoie Y, et al. Detection of a new variant of rabbit hemorrhagic disease virus in France. Vet Rec. 2011;168 (5):137–8.

10. Capucci L, Cavadini P, Schiavitto M, Lombardi G, Lavazza A. Increased pathogenicity in rabbit hemorrhagic disease virus type 2 (RHDV2). Vet Rec 2017; 180(17): 426. doi: 10.1136/vr.104132

11. Fahmy HA, Arafa A, Mahmoud AH. Molecular diagnosis of rabbit hemorrhagic disease virus (RHDV). Egypt. J. Comp. Path. & Clinic. Path. 2010; 23 (1): 85–101.

12. Ferreira PG, Costa-e-Silva A, Monteiro E, Oliveira MJ, Aguas AP. Transient decrease in blood heterophils and sustained liver damage caused by calicivirus infection of young rabbits that are naturally resistant to rabbit hemorrhagic disease. Res Vet Sci 2004;76(1):83-94.

13. El-Jakee JK, Moussa IM, Omran MS, Ahmed BM, Elgamal MA, Hemeg HA, et al. A novel bivalent Pasteurellosis-RHD vaccine candidate adjuvanted with Montanide ISA70 protects rabbits from lethal challenge. Saudi J. Biol. Sci.2019;27(3):996-1001.

14. Camarda A, Pugliese N, Cavadini P, Circella E, Capucci L, Caroli A, Legretto M, Mallia E, Lavazza A. Detection of the new emerging rabbit haemorrhagic disease type 2 virus (RHDV2) in Sicily from rabbit (Oryctolagus cuniculus) and Italian hare (Lepus corsicanus). Res Vet Sci.2014;97(3):642-5.

15. Le Gall-Reculé G, Lavazza A, Marchandeau S, Bertagnoli S, Zwingelstein F, Cavadini P, et al. Emergence of a new lagovirus related to Rabbit Hemorrhagic Disease Virus. Vet Res.2013;44:81.

16. Abd El-Moaty DA, El-Bagoury GF, El-Zeedy SA, Salman OG. Egyptian non-hemagglutinating isolates of rabbit hemorrhagic disease virus can change to variable HA profile. Benha Vet. Med. J.2014;26(2):71-83.

17. Hansen B, Sokolovska A, HogenEsch H, Hem SL. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine.2007;25(36):6618-24.

18. Hogenesch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol.2013;3:406.

19. Shevchenko AA. Basic properties of new lyophilized and inactivated vaccine against viral hemorrhagic disease of rabbits. Russ Agric Sci.1994;6:24-8.

20. Amal IM, Daoud AM, El-Bourdiny F. Preparation of inactivated infectious bronchitis virus disease vaccine using new oil adjuvant private. Vet. Med. J. 2005;53(2):329-39.